Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftaroline Fosamil

FDA-approved product (powder, intravenous), marketed as Ceftaroline Fosamil, Teflaro.

Registered studies
50+
Lab records
19
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftaroline Fosamil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cephalosporins and penems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DI02

Repurposing investigation

Ceftaroline Fosamil is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA75.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli74.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae92.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 13 of 19 lab records
Open Ceftaroline Fosamil in ChEMBL Registered studies below
Show the 19 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftaroline Fosamil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

    NCT07376889 · start 2026-02-01

    Registered record
    Registry ID
    NCT07376889
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2029-01
    Enrolment
    2,096

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
    PhasePhase 4
    Registry statusRecruiting

  • Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

    NCT07228702 · start 2026-01-11

    Registered record
    Registry ID
    NCT07228702
    Conditions
    Non-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
    Interventions
    Mycobacteriophage Muddy_HRMN0052; Amikacin Injection; Clofazimine; Bedaquiline (B); Linezolid (LZD); Sulfamethoxazole/Trimethoprim; Imipenem + Cilastatin; Ceftaroline fosamil; Omadacycline Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Enrolling by invitation
    Start
    2026-01-11
    Completion
    2027-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Tuberculous Mycobacterial (NTM) Pneumonia; Mycobacterium Abscessus Infection
    InterventionMycobacteriophage Muddy_HRMN0052; Amikacin Injection; Clofazimine; Bedaquiline (B) +5 more
    PhasePhase 1
    Registry statusEnrolling by invitation

  • Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

    NCT06294600 · start 2024-02-12

    Registered record
    Registry ID
    NCT06294600
    Conditions
    Community-acquired Pneumonia
    Interventions
    Clarithromycin 500mg; Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-02-12
    Completion
    2026-07-30
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia
    InterventionClarithromycin 500mg; Tablets
    PhasePhase 3
    Registry statusRecruiting

  • Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients

    NCT06688084 · start 2024-01-01

    Registered record
    Registry ID
    NCT06688084
    Conditions
    Diabetic Foot Ulcer
    Interventions
    Molecular epidemiology of the collection; Study of the resistome of the S. pettenkoferi population; Study of the virulome of the S. pettenkoferi population; Study of the resistance profiles of all S. pettenkoferi isolates; Selection of strains for in-depth phenotypic study; Selection of strains (n=3) for the virulence study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-01-01
    Completion
    2026-05-01
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Foot Ulcer
    InterventionMolecular epidemiology of the collection; Study of the resistome of the S. pettenkoferi population; Study of the virulome of the S. pettenkoferi population; Study of the resistance profiles of all S. pettenkoferi isolates +2 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • Comparing Oral Versus Parenteral Antimicrobial Therapy

    NCT05977868 · start 2023-08-04

    Registered record
    Registry ID
    NCT05977868
    Conditions
    Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary Infection
    Interventions
    Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-08-04
    Completion
    2025-02-14
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection +2 more
    InterventionAmoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    PhasePhase 4
    Registry statusTerminated

  • Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

    NCT05156437 · start 2022-03-16

    Registered record
    Registry ID
    NCT05156437
    Conditions
    Endocarditis
    Interventions
    Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin; Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-03-16
    Completion
    2024-10-31
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis
    InterventionAmoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin; Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
    PhasePhase 4
    Registry statusTerminated

  • Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries

    NCT04198571 · start 2020-05-17

    Registered record
    Registry ID
    NCT04198571
    Conditions
    Community Acquired Pneumonia; Complicated Skin and Soft Tissue Infection
    Interventions
    Zinforo (ceftaroline fosamil)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-05-17
    Completion
    2021-08-30
    Enrolment
    317

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia; Complicated Skin and Soft Tissue Infection
    InterventionZinforo (ceftaroline fosamil)
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI

    NCT04409769 · start 2020-02-01

    Registered record
    Registry ID
    NCT04409769
    Conditions
    Bone and Joint Infection; Antibiotic Reaction
    Interventions
    Description of use of ceftaroline and ceftobiprole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-01
    Completion
    2020-05-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone and Joint Infection; Antibiotic Reaction
    InterventionDescription of use of ceftaroline and ceftobiprole
    PhaseNot recorded
    Registry statusCompleted

  • Study to Optimize the Use of New Antibiotics

    NCT03941951 · start 2019-07-09

    Registered record
    Registry ID
    NCT03941951
    Conditions
    Bacterial Infections; Fungal Infection
    Interventions
    Non-impositive Program for Optimizing the Use of Antimicrobials
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-07-09
    Completion
    2022-12-31
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections; Fungal Infection
    InterventionNon-impositive Program for Optimizing the Use of Antimicrobials
    PhaseNot applicable
    Registry statusUnknown

  • Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy

    NCT04152694 · start 2018-03-09

    Registered record
    Registry ID
    NCT04152694
    Conditions
    Infection During Renal Replacement Therapy; Critically Ill
    Interventions
    Ceftaroline levels in CRRT
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-09
    Completion
    2020-09-01
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection During Renal Replacement Therapy; Critically Ill
    InterventionCeftaroline levels in CRRT
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

    NCT03771313 · start 2017-09-01

    Registered record
    Registry ID
    NCT03771313
    Conditions
    Cystic Fibrosis
    Interventions
    Ceftaroline
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-09-01
    Completion
    2025-07-31
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionCeftaroline
    PhaseNot recorded
    Registry statusCompleted

  • Antibiotic Prophylaxis in Open Fractures

    NCT02937181 · start 2016-12

    Registered record
    Registry ID
    NCT02937181
    Conditions
    Open Fractures
    Interventions
    Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-12
    Completion
    2019-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Fractures
    InterventionCeftaroline
    PhasePhase 4
    Registry statusUnknown

  • Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance

    NCT03025841 · start 2016-12

    Registered record
    Registry ID
    NCT03025841
    Conditions
    Pneumonia
    Interventions
    Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-12
    Completion
    2018-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionCeftaroline
    PhasePhase 1
    Registry statusCompleted

  • Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

    NCT02600793 · start 2016-08

    Registered record
    Registry ID
    NCT02600793
    Conditions
    Cerebrospinal Fluid Shunts; Ventriculoperitoneal Shunt
    Interventions
    Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2019-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebrospinal Fluid Shunts; Ventriculoperitoneal Shunt
    InterventionCeftaroline
    PhasePhase 1
    Registry statusUnknown

  • Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

    NCT02735707 · start 2016-04-11

    Registered record
    Registry ID
    NCT02735707
    Conditions
    Community-acquired Pneumonia, Influenza, COVID-19
    Interventions
    Ceftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline; Amoxicillin-clavulanate; Standard course macrolide; Extended course macrolide; No systemic corticosteroid; Fixed-duration Hydrocortisone; Shock-dependent hydrocortisone; Fixed-duration higher dose Hydrocortisone; No antiviral agent for influenza; Five-days oseltamivir; Ten-days oseltamivir; No antiviral agent for COVID-19; Lopinavir / Ritonavir; Hydroxychloroquine; Hydroxychloroquine + lopinavir/ritonavir; Ivermectin; No immune modulation for COVID-19; Interferon beta-1a; Anakinra; Tocilizumab; Sarilumab; Local standard venous thromboprophylaxis; Therapeutic dose anticoagulation; Conventional low dose thromboprophylaxis; Intermediate dose thromboprophylaxis; Continuation of therapeutic dose anticoagulation; No immunoglobulin; Convalescent plasma; Delayed administration of convalescent plasma; No vitamin C; Vitamin C; No antiplatelet; Aspirin; P2Y12 inhibitor; No simvastatin; Simvastatin; Eritoran; Apremila
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2016-04-11
    Completion
    2028-02
    Enrolment
    20,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia, Influenza, COVID-19
    InterventionCeftriaxone; Moxifloxacin or Levofloxacin; Piperacillin-tazobactam; Ceftaroline +37 more
    PhasePhase 3
    Registry statusRecruiting